DEA Approval Necessary to Act on Recent Amendments to Illinois Law Granting APNs and PAs the Authority to Prescribe Schedule II Controlled Substances
Healthcare Alert | 1 min read
Feb 5, 2010
In August 2009, three Illinois Acts were amended, granting Advanced Practice Nurses (APNs) and Physician Assistants (PAs) the authority to prescribe Schedule II controlled substances. The Illinois Nurse Practice Act, Physician Assistant Act and Controlled Substances Act that had previously authorized the delegation of prescriptive authority (pursuant to a written collaborative or supervision agreement) only in regard to Schedule III-V controlled substances, now permit the delegation of such authority for Schedule II substances. Despite the state law amendments, however, APNs and PAs practicing in Illinois must await formal DEA approval before registering for updated state and federal controlled substances registration.
Under the amended Acts, APNs and PAs will have limited prescriptive authority. Specifically, APNs and PAs may be delegated no more than five Schedule II controlled substances by oral dosage and all prescriptions must be limited to no more than a 30-day oral dosage. In addition, only those controlled substances that the collaborating or supervising physician prescribes may be delegated, and the APN or PA must meet with the collaborating or supervising physician monthly to discuss the condition of those patients for whom a controlled substance is prescribed.
DEA approval is expected later this year. Upon approval, the Illinois Department of Financial and Professional Regulation will release updated forms and applications for revised controlled substances registration. After acquiring proper state registration, APNs and PAs will be required to apply for a revised or updated DEA number. Both must be obtained prior to acting upon the delegation of authority permitted under the recent statutory amendments.
For more information, please contact Stephen T. Moore or your regular Hinshaw attorney.
This alert has been prepared by Hinshaw & Culbertson LLP to provide information on recent legal developments of interest to our readers. It is not intended to provide legal advice for a specific situation or to create an attorney-client relationship.
Related People
Related Capabilities
Featured Insights

Lawyers' Lawyer Newsletter
Nov 19, 2026
Private Capital and Professional Independence: MSOs and the Changing Business of Law

In The News
Nov 18, 2026
William Schubert: Why Client Confidentiality Reigns Supreme for Motions to Withdraw
![[Byline] Revisiting Disparate Impact Liability Under Executive Order 14281](/a/web/9w8wghM45uReApTZbaaDqe/eFisyR/examining-disparate-impact-liability-in-financial-services-under-executive-order-14281-insights.jpg)
In The News
Nov 18, 2026
[Byline] Revisiting Disparate Impact Liability Under Executive Order 14281

In The News
Nov 17, 2026
Justin Penn Examines FCRA Trends Involving “Legal vs. Factual Inaccuracy” Defense

Consumer Crossroads: Where Financial Services and Litigation Intersect
Nov 16, 2026
SCOTUS to Decide: Are Bankruptcy Stay Violations Arbitrable?

Press Release
Nov 13, 2026
Hinshaw Advises Client Safe Harbor Capital Partners in $44 Million Financing

In The News
Nov 12, 2026
Spencer Kook Authors Article Providing a Claims Manager’s Guide to Class Action Exposure

In The News
Nov 12, 2026
Mitch Chargo Discusses Cannabis M&A Implications in a Post-Rescheduling Landscape

Webinar
Nov 12, 2026
Michael Adams Presents on Navigating Ethics in the Digital Age

Event
Nov 12, 2026
Cathy Mulrow-Peattie Discusses AI and Supply Chain Cybersecurity

Healthcare Alert
Nov 11, 2026
Illinois Enacts 340B Contract Pharmacy Protections: 7 Steps Covered Entities Should Take


